- About Us
- Image Gallery
Published on : Saturday, November 30, 2013
VILLA GUARDIA (COMO), Italy, November 26, 2013 (Globe Newswire) — Gentium S.p.A. (NASDAQ: GENT) (the “Company”) today announced that an oral presentation and a poster on Defibrotide will be presented at the 55th Annual Meeting and Exposition of the American Society of Hematology to be held at the Ernst N. Morial Convention Center in New Orleans, LA, December 7-10, 2013.
Results of a Large Prospective Study on the Use of Defibrotide in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome – Updated Results of a Treatment IND (T-IND) Expanded Access Protocol.
Monday, December 9, 2013: 4:30 PM-6.00 PM, R06-R07, Ernst N. Morial Convention
Center, Paul G. Richardson, RJ Corman Professor of Medicine, Clinical Director Jerome
Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute Harvard Medical School,
Boston, MA (USA).
Impact Of Prophylaxis With Defibrotide On The Occurrence Of Acute GvHD In Allogeneic HSCT Monday, December 9, 2013: 6:00 PM-8:00 PM, Hall G, Ernst N. Morial Convention Center, Selim Corbacioglu, Chair of the Dept. of Paediatric Haematology and Oncology Children’s Hospital University of Regensburg, Germany.
Source:- Gentium Spa